Article first published online: 13 Sep 2019
The photodermatoses affect large proportions of the population but their impact on quality of life (QoL) and psychological health has not been reviewed. Several tools are available to evaluate QoL and psychological impacts.
To systematically review current literature to identify tools used to assess QoL and psychological impacts in patients with photodermatoses, and to summarize the reported findings.
A systematic search of PubMed, OVID Medline, PsycInfo and CINAHL was performed for articles investigating QoL and/or psychological impact in patients with photodermatoses, published between 1960 and September 2018.
Twenty studies were included: 19 incorporated QoL assessment while three evaluated psychological morbidity. Six QoL tools were found to be used: Dermatology Life Quality Index ( DLQI ), Children’s DLQI , Family DLQI , Skindex (16‐ and 29‐item versions), Erythropoietic Protoporphyria Quality of Life ( EPP ‐QoL) and EuroQol. Between 31% and 39% of photosensitive patients reported a very large impact on QoL ( DLQI > 10). Employment and education, social and leisure activities, and clothing choices were particularly affected. Only one tool was specifically designed for a photodermatosis ( EPP ‐QoL). Four tools were used to evaluate psychological impact: the Hospital Anxiety and Depression Scale, Fear of Negative Evaluation, brief COPE and Illness Perception Questionnaire‐Revised. Levels of anxiety and depression were approximately double British population data. Patients with facial involvement, female gender and younger age at onset showed more psychological morbidity.
Several tools have been used to assess QoL in the photodermatoses, and confirm substantial impact on QoL. Development of specific, validated QoL measures would address their unique impacts. Research delineating their psychological comorbidity is sparse and requires further exploration.
What’s already known about this topic?
What does this study add?
20 Oct 2019
A randomized, double-blind placebo-controlled study found that ASN002, an oral, dual Janus kinase and spleen tyrosine kinase inhibitor, had promising efficacy and safety profile for patients with moderate-to-severe atopic dermatitis. https://t.co/9CCBbbM8HV #AD #clinicaltrial https://t.co/x1ueJO8Cny
19 Oct 2019
52F w/ numerous nonpruritic erythematous to brownish annular plaques that gradually expanded centrifugally & coalesced into polycyclic & reticulate appearance w/ partial central atrophy & elevated borders on sun‐exposed areas. What's your Dx? https://t.co/86xi2tenD5 #dermtwitter https://t.co/ZW1DFlJhpG
19 Oct 2019
Skin fibrosis (scarring) remains challenging to assess. This study looks at the utility of using high frequency ultrasound and optical coherence tomography to provide a numerical score of skin fibrosis during the course of wound healing. https://t.co/c5UyZrZrjk #ultrasound #OCT https://t.co/pmBQhGNpcj
18 Oct 2019
This population-based study of over 160,000 participants found that seborrheic dermatitis is a common disease (3.2% of study population) that is more prevalent in men and older individuals. https://t.co/lr5QwCd5J8 #seborrhea #dermatology #epidemiology https://t.co/6M49ovPUed
18 Oct 2019
RT Dominique du Crest @ducrest: Management of psoriasis as a systemic disease: what is the evidence? https://t.co/Q8HsEMILgn via @BrJDermatol Biological treatment may prevent or reverse inflammatory damage associated with psoriasis comorbidities. #dermatology #dermatologia #PsoriasisAwareness